Cancer
Researchers from King Abdulaziz City for Science and Technology (KACST) have made a breakthrough in cancer gene therapy by exploring unconventional immunotherapy platforms. These novel approaches leverage diverse immune cell subsets and synthetic biologics to overcome the limitations of traditional immunotherapies. According to the study, unconventional immunotherapies have the potential
Cancer
Research from King Abdulaziz City for Science and Technology (KACST) has shed light on the potential of cancer gene therapy with the introduction of innovative nanoparticle-based approaches. This new paradigm shift in cancer treatment leverages the host's immune system to combat established tumors, but existing methods have limitations,
Cancer
The World Health Organization (WHO) has published updated editions of its Model List of Essential Medicines (EML) and Essential Medicines for Children (EMLc) to include new treatments for several cancers and for diabetes and related conditions such as obesity. The updated lists highlight medicines that address priority health needs worldwide
Cancer research
Fresh data on Oncology - Small Bowel Cancer have been presented in a new report by researchers at the Mashhad University of Medical Sciences. The study, which examined the current evidence on targeted therapy and immunotherapy for Small Bowel Cancer (SBC), found that these treatments may have the potential to
Cancer research
China has emerged as a leader in the development of CAR-T cell therapy, a cornerstone of personalized medicine for hematologic malignancies, with rapid advancements in domestically developed CAR-T therapies achieving clinical outcomes comparable to global benchmarks. Although successes have been reported, CAR-T application in solid tumors remains hindered by various
Cancer research
Researchers at the Wistar Institute have made a groundbreaking discovery that could potentially lead to a new therapeutic target for ovarian and other cancers. By targeting a specific cleft in the retinoblastoma protein, scientists were able to kill tumor-protecting macrophages, making the tumor cells more vulnerable to immune attack. This
Cancer research
The global non-small cell lung cancer (NSCLC) treatment market is experiencing significant growth, driven by advancements in immunotherapies, targeted therapies, and a rising global incidence of lung cancer. Innovations in immune checkpoint inhibitors, such as pembrolizumab and nivolumab, have revolutionized the treatment landscape by offering improved survival rates, particularly in
Cancer
Swiss Cancer Institute has launched a Phase 2 clinical trial to investigate the efficacy of combining gemcitabine with ivonescimab in patients with advanced non-small cell lung cancer (NSCLC) who have experienced disease progression following chemoimmunotherapy (CIT). The trial aims to enroll 47 participants from the USA and will evaluate the
Cancer research
A new study from Cedars-Sinai Medical Center has found that young women with breast cancer who underwent chemo-immunotherapy treatment experienced early cardiovascular toxicity, even with a low cardiovascular risk profile. Researchers retrospectively analyzed 85 women with early-stage triple-negative breast cancer who received chemotherapy and pembrolizumab between 2018 and 2023. The
Immunotherapy
Investigators from the First Affiliated Hospital and other Chinese institutions published a new report on the effectiveness of immunotherapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC) who have developed resistance to tyrosine kinase inhibitors (TKIs). The study analyzed comprehensive treatment data from 312 patients with EGFR-mutant NSCLC, focusing
Cancer research
Researchers from Affiliated Hospital of Qinghai University have conducted a systematic review and network meta-analysis to evaluate the efficacy and safety of combination therapies with immune checkpoint inhibitors (ICIs) in patients with non-small cell lung cancer (NSCLC) and liver metastases. The study aimed to determine the most effective first-line ICI
Cancer
New research from the Keck School of Medicine of USC has shed light on the mechanisms behind human papillomavirus (HPV)-linked cancers, specifically the role of a signaling protein, Interleukin-23 (IL-23), in undermining the body's defenses. The study found that blocking IL-23 boosts the effectiveness of experimental treatments
